(Q38073812)

28 August 2017

1 reference

title

Vascular-disrupting agents in oncology (English)

1 reference

28 August 2017

Monica M Mita

1

1 reference

28 August 2017

Liza Sargsyan

series ordinal

2

1 reference

28 August 2017

Alain C Mita

series ordinal

3

1 reference

28 August 2017

Matt Spear

series ordinal

4

1 reference

28 August 2017

language of work or name

English

0 references

publication date

15 January 2013

1 reference

Expert Opinion on Investigational Drugs

28 August 2017

published in

1 reference

28 August 2017

volume

22

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

317-328

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Modeling of angioadaptation: insights for vascular development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Vascular attack as a therapeutic strategy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Disrupting tumour blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

The biology of the combretastatins as tumour vascular targeting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Distinct signaling pathways of microtubule inhibitors--vinblastine and Taxol induce JNK-dependent cell death but through AP-1-dependent and AP-1-independent mechanisms, respectively.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Phase I trial of combretastatin a-4 phosphate with carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

AVE8062: a new combretastatin derivative vascular disrupting agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.759557

10.1517/13543784.2013.759557

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference